Literature DB >> 11145853

Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients.

E Takeuchi1, H Yanagawa, Y Suzuki, K Shinkawa, H Bando, S Sone.   

Abstract

Deviation of type 1/type 2 cytokine balance to type 2 predominance may contribute to tumour progression. We investigated effect of interleukin (IL-)15 on modulation of type 1/type 2 balance in addition to non-major histo-compatibility complex (MHC)-restricted killer induction in the tumour-growing site. IL-15 induced significant killer activity in mononuclear cells (MNC) in malignant pleural effusion as well as those in peripheral blood. Pleural MNC produced more IFN-gamma (type 1 cytokine) by incubation with IL-15 or IL-2 than blood MNC. Moreover, IL-4 and IL-5 (type 2 cytokines) production by pleural MNC were observed only by incubation with IL-2, but not with IL-15. These observations suggest that IL-15 has a potent activity to restore type 1/type 2 balance in addition to killer induction in tumour-growing site. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145853     DOI: 10.1006/cyto.2000.0808

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  3 in total

1.  IL-15 in human visceral leishmaniasis caused by Leishmania infantum.

Authors:  S Milano; G Di Bella; P D'Agostino; C Barbera; R Caruso; M La Rosa; V Ferlazzo; G Vitale; C La Russa; G Gambino; N Chifari; S Mansueto; E Cillari
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

2.  Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women.

Authors:  Alison L Van Dyke; Michele L Cote; Angie S Wenzlaff; Wei Chen; Judith Abrams; Susan Land; Craig N Giroux; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

3.  The role of IL15 gene variants in visceral leishmaniasis among Iranian patients.

Authors:  Manoochehr Rasouli; Mehdi Kalani; Simin Kiany
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.